Cohort profile update: the main and new findings from the SaMi-Trop Chagas cohort

ABSTRACT The SaMi-Trop project is a cohort study conducted in 21 municipalities of endemic areas of Chagas disease, including 1,959 patients with chronic Chagas cardiomyopathy. In this article we updated the results of the project, adding information from the second cohort visit. Trypanosoma cruzi-s...

Full description

Bibliographic Details
Published in:Revista do Instituto de Medicina Tropical de São Paulo
Main Authors: Claudia Di Lorenzo Oliveira, Clareci Silva Cardoso, Nayara Ragi Baldoni, Larissa Natany, Ariela Mota Ferreira, Lea Campos de Oliveira, Maria do Carmo Pereira Nunes, Nayara Dornela Quintino, Ana Luiza Bierrenbach, Lewis F. Buss, Desiree Sant’Ana Haikal, Edecio Cunha Neto, Antonio Luiz Pinho Ribeiro, Ester Cerdeira Sabino
Format: Article in Journal/Newspaper
Language:English
Published: Universidade de São Paulo (USP) 2021
Subjects:
Chagas disease
Neglected diseases
Chagas cardiomyopathy
Cohort studies
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
sami
Online Access:https://doi.org/10.1590/s1678-9946202163075
https://doaj.org/article/83c7b9e62386418883cf6329063c3e4b
Description
Summary:ABSTRACT The SaMi-Trop project is a cohort study conducted in 21 municipalities of endemic areas of Chagas disease, including 1,959 patients with chronic Chagas cardiomyopathy. In this article we updated the results of the project, adding information from the second cohort visit. Trypanosoma cruzi-seropositive patients were enrolled from the primary care Telehealth service in Minas Gerais State, Brazil. The eligibility criterium for the second visit was the participation in the baseline evaluation. Of 1,959 participants at the baseline assessment, 1,585 (79.9%) returned after two years for the second evaluation. The mortality rate was 6.7%, but varied from 0.9% to 18.2% when it was stratified by certain clinical characteristics. A lower age-adjusted NT-Pro-BNP level (less than 300) and a prior benznidazole treatment were associated with lower mortality. There was an improvement in most quality of life domain scores. Participants have also reported fewer signs and symptoms and greater use of medication. The second follow-up visit will be complete in Oct 2021.

Similar Items